Navigation Links
Rottenstein Law Group LLP Responds to Study Linking Pradaxa Side Effects with Potential Mortality Risks

(PRWEB) May 13, 2013

A major medical journal published a study this month that reported an alleged increase in deaths in patients with closed head injuries who use the blood thinner Pradaxa.* The Pradaxa attorneys at the Rottenstein Law Group LLP acknowledge the study’s results, noting that excessive bleeding is among the drug’s alleged side effects the firm hears about from prospective Pradaxa plaintiffs.

A cohort of Palm Beach County, Florida, surgeons reviewed data from procedures on adults over 18 years old who suffered different types of closed head injuries and then determined if the patients were using warfarin, Pradaxa (dabigatran), or were not using any anticoagulation drugs, according to the study published in the May 1, 2013, edition of the Journal of Neurosurgery.

“Alleged excessive bleeding incidents are at the center of Pradaxa lawsuits in federal court,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP, referring to a multidistrict litigation formed in federal court in Illinois (In re Pradaxa Products Liability Litigation, MDL-2385, U.S. District Court for the Southern District of Illinois (East St. Louis)).

The Rottenstein Law Group LLP encourages those who were allegedly harmed by Pradaxa to visit the firm’s website to download a free brochure to help them determine if they have a case.


For the latest news on defective medications and medical devices and related lawsuits, visit the Rottenstein Law Group LLP’s Injury Lawyer Newswire at Readers can subscribe to the news site’s stories and videos to stay on top of personal injury news.

The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices. (Attorney advertising. Prior results do not guarantee a similar outcome.)

The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
# 804
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com


Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Byetta Lawsuit News: Woman Alleges Her Thyroid Cancer Is Linked to Byetta Use, Rottenstein Law Group LLP Reports
2. Da Vinci Surgical Robot Lawsuit News: Robot Maker Says Device Could Cause Internal Burns, Notes Rottenstein Law Group LLP
3. Lipitor Lawsuit News: US Spending on Drugs Fell For First Time in 2012, Notes Rottenstein Law Group LLP
4. DePuy ASR Lawsuit Update: Rottenstein Law Group Comments on Delay of Second Federal Trial
5. Lipitor Lawsuit News: Rottenstein Law Group Comments on FDA Approval of New Drug With Lipitor Compound
6. NuvaRing Lawsuit News: Rottenstein Law Group Responds to Judge’s Refusal to Dismiss Punitive Damages Claims
7. Rottenstein Law Group Notes Medical Journal Article Advising Doctors To Use Caution When Prescribing Zithromax and Other Antibiotics
8. Da Vinci Surgical Robot Lawsuit News: Rottenstein Law Group Comments on Testimony in Ongoing Robot Trial
9. Fosamax Lawsuits Update: Rottenstein Law Group Responds to Femur Fracture Verdict in Merck’s Favor
10. DePuy ASR Lawsuit Update: Rottenstein Law Group Addresses J&J Motion to Appeal $8.3 Million Verdict
11. Stryker Hip Replacement Lawsuit News: Mass. Woman Files First Known Federal Stryker ABG II Hip Lawsuit, Rottenstein Law Group Reports
Post Your Comments:
(Date:10/13/2015)... ... 13, 2015 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... Commitment to Cure last night at the Mandarin Oriental in New York City. ...
(Date:10/13/2015)... ... October 13, 2015 , ... The documentary Pink & Blue: Colors ... Beverly Hills October 2 - 8, coinciding with National Hereditary Breast & Ovarian Cancer ... takes us through the lives of women - and men - who are dealing ...
(Date:10/13/2015)... ... October 13, 2015 , ... Purdue University ... the Life Sciences Initiative aimed at enhancing Purdue’s life sciences research and graduate ... True” capital campaign. , The investment will result in cohesive efforts across several ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... enterprise focused on cancer patients, today announced a new partnership with the ... battling this rare type of non-Hodgkin’s lymphoma, their families and physicians. , ...
(Date:10/13/2015)... Diego, CA (PRWEB) , ... October 13, 2015 ... ... launch of its newest technology platform, ENGAGE, at HIMSS’s Patient Engagement Summit ... to end. , ENGAGE delivers innovative health programs and interventions via mobile devices ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)...  Graduate students across the country, with an ... soon have the opportunity to learn about a ... discovery and development process. Eli Lilly and Company ... leaders from academic institutions to create an elective ... Drug Development."  Lilly will formally unveil the eLearning ...
(Date:10/13/2015)... SAN FRANCISCO , October 13, 2015 ... expected to reach USD 26.8 billion by 2022, according ... Anesthesia and respiratory devices, owing to their capability to ... expected to witness a substantial growth. --> ... reach USD 26.8 billion by 2022, according to a ...
(Date:10/13/2015)... , Oct. 13, 2015   Micell Technologies ... DESSOLVE I and II trials of its MiStent Sirolimus ... ® ) were presented at the 27th Annual ... San Francisco , October 11-15. TCT ... cardiovascular medicine. MiStent SES was designed to optimize vessel ...
Breaking Medicine Technology: